The Provisional Gap: Priority, Intervening Publication and National Phase
On 5 March 2024 an inventor files a US provisional application describing a lithium electrode coated with 'coating A'. On 4 March 2025 he files a PCT application claiming priority from the provisional. The PCT application adds a claim to 'coating A containing 2% by weight graphene' and includes new test data for that embodiment; the provisional had no graphene. The PCT application is published on 11 September 2025. On 1 June 2024 a competitor published an article disclosing coating A without graphene. The inventor enters the Malaysian national phase on 2 September 2026, filing an English translation and paying the fees. The Malaysian examiner cites the competitor article against both claim 1 (coating A plus 2% graphene) and claim 2 (coating A alone). The inventor says the provisional priority date protects everything. The client also asks whether the 2 September entry is late because the 30-month date was 5 September 2026.
1. Determine the effective date for each claim and explain the effect of the competitor's article.
Read the worked answer
Priority is claim-by-claim and feature-by-feature. Claim 2 is for coating A alone. That subject matter is disclosed in the provisional, so claim 2 is entitled to the 5 March 2024 priority date. The competitor's article was published on 1 June 2024, after that date. It is therefore not prior art against claim 2, and the examiner's citation against claim 2 is wrong on priority.
Claim 1 requires coating A plus 2% by weight graphene. The provisional does not disclose graphene at all. The graphene feature is not merely an optional detail; it is part of the claimed combination. Claim 1 is therefore not entitled to the provisional date for that combination. Its effective date is the PCT filing date, 4 March 2025. The competitor's article of 1 June 2024 is prior art against claim 1.
Does the article anticipate claim 1? It discloses coating A without graphene. It therefore does not expressly disclose the 2% graphene feature, so it is not a novelty-destroying disclosure of the whole claim. But it is highly relevant to inventive step: the examiner may argue that adding 2% graphene to coating A was obvious in view of the article and common general knowledge. The new test data in the PCT cannot create priority; it can only support the PCT filing. The client should not assume that the provisional protects the graphene claim.
2. Advise on the national phase timing and documents, including the client's concern about the 2 September entry.
Read the worked answer
The Malaysian national phase deadline is 30 months from the priority date. The earliest priority date is 5 March 2024. Thirty months from that date is 5 September 2026. The entry on 2 September 2026 is therefore three days early, not late. The client's concern is based on a miscalculation; no extension or restoration is needed on these dates.
The national phase file should include the PCT request, the international application in English or a verified English translation, the international search report and any international preliminary examination report, the priority document if not already available through the PCT system, and the prescribed fees. The applicant should confirm that the name and address on the Malaysian entry match the PCT applicant and that any assignment from the inventor is recorded. If the PCT was filed in a language other than English, the translation must be accurate and complete; a defective translation can affect claim scope.
The client should also check whether the Malaysian entry was made in the applicant's name and whether the priority claim was correctly indicated. If the priority claim is later found to be partly invalid, that does not make the national phase entry late; it affects the prior art date. The immediate step is to confirm the entry receipt and then respond to the examiner on the priority issue, not to seek late entry.
3. Advise on amendment strategy for claim 1, including whether the graphene claim can be saved.
Read the worked answer
The graphene claim can be saved only if there is a basis in the PCT application as filed and if the amended claim is novel and inventive over the 1 June 2024 article. The PCT application contains the 2% graphene embodiment and test data, so the feature itself is supported. The problem is priority, not added matter.
A first option is to keep claim 1 but narrow it to a specific graphene parameter that is disclosed and that the article does not suggest. For example, if the PCT describes a particular graphene particle size, dispersion method or surface treatment, that feature can be added from the PCT as filed. The narrower claim may still be obvious, so the client should gather comparative data showing an unexpected effect over coating A without graphene. That data must already be in the PCT or be supportable from it; new experimental data can be submitted as evidence of effect, but it cannot be used to add a feature that was not disclosed.
A second option is to delete claim 1 and rely on claim 2, which has the provisional priority date. That preserves a valid but narrower monopoly. A third option is to file a divisional directed to the graphene embodiment if the PCT support is adequate, but a divisional does not change the prior art date; it inherits the same priority position.
My advice is to keep claim 2, amend claim 1 only with disclosed parameters, and prepare an inventive-step argument based on the specific graphene distribution or an effect that the article does not teach. The client should be told that the provisional does not protect the graphene combination and that the 1 June 2024 article is a real risk for claim 1.